Skip to main content

Vitiligo Treatment in the UAE: What the New Oral Pill Means for Patients

A
Amna Abdullah
November 7, 2026 · 5 min read
Amna Abdullah, Medifinder Editorial Team
Reviewed by Amna Abdullah, Medifinder Editorial Team on November 7, 2026
Vitiligo Treatment in the UAE: What the New Oral Pill Means for Patients

Vitiligo treatment in the UAE now includes a once-daily pill

Vitiligo treatment in the UAE has a new option: a once-daily oral medicine for non-segmental vitiligo, approved by the Emirates Drug Establishment (EDE). The Emirates Dermatology Society says the treatment is being launched at its 10th Emirates Dermatology Conference, held in Dubai from 6 to 8 November 2026.

Is there an oral pill for vitiligo in the UAE?

Yes. In August 2026 the EDE approved RINVOQ (upadacitinib) for adults and teenagers aged 12 and over with non-segmental vitiligo whose condition needs systemic treatment, meaning a medicine that works through the whole body. It is a prescription medicine, so a dermatologist decides whether it suits you.

What was announced at the Dubai dermatology conference

The 10th Emirates Dermatology Conference, organised by the Emirates Dermatology Society, is taking place at the InterContinental Dubai Festival City. Local media reported that more than 500 doctors and specialists are attending.

  • Oral vitiligo treatment: Dr Ayman Alnaeem, president of the Emirates Dermatology Society and chair of the conference, said the event would include the launch of an innovative oral treatment for vitiligo, and that the UAE is the first country in the world to approve it.
  • Psoriasis: the society said the conference would also present the latest generation of biologic treatments for psoriasis. Specific medicines were not named in the reports we reviewed.
  • Other topics: the programme covers eczema, acne, skin ageing, skin cancer, and the use of AI and imaging in dermatology.

The oral vitiligo pill approved in the UAE

The EDE announced its approval on 17 August 2026. According to Gulf News and Khaleej Times:

  • Medicine: RINVOQ (upadacitinib), taken by mouth once a day.
  • Who it is for: adults and adolescents aged 12 and over with non-segmental vitiligo who need systemic therapy.
  • What the EDE said: it described the medicine as the first licensed oral treatment for this group of patients and said the UAE is the first country to approve this use.
  • Elsewhere: the maker, AbbVie, announced that the European Commission approved the same use on 29 July 2026. AbbVie says the US application is still under FDA review.

How the oral vitiligo treatment works

Vitiligo happens when the cells that give skin its colour (melanocytes) are destroyed, leaving pale or white patches. An immune reaction is thought to be a main cause. Upadacitinib is a JAK inhibitor: according to AbbVie, it blocks signals inside immune cells (mainly JAK1) that drive inflammation.

  • Dose in Europe: 15 mg once a day, per AbbVie.
  • Evidence: the approval in Europe was based on two Phase 3 studies called Viti-Up, with 614 people at 90 sites. AbbVie says the medicine beat placebo after 48 weeks on both main goals: repigmentation of the whole body and of the face.
  • Safety: like other JAK inhibitors, it carries warnings about serious infections, shingles, blood clots, heart events and some cancers, and is not used in pregnancy. Doctors usually screen for TB and check blood tests first.

Who should consider vitiligo treatment in the UAE

Vitiligo affects roughly 0.5 to 1% of people worldwide, according to Gulf News. Non-segmental vitiligo, which causes patches on both sides of the body that can spread over time, is by far the most common type: AbbVie puts it at 84% of cases.

  • It is not contagious: you cannot catch vitiligo from someone else.
  • Not every white patch is vitiligo: other skin conditions can look similar, so a proper diagnosis matters.
  • Linked conditions: vitiligo has been linked to thyroid disease, psoriasis, rheumatoid arthritis, alopecia areata and diabetes, so your doctor may suggest tests.
  • Results take time: in the main studies, results were measured after 48 weeks of treatment.

Vitiligo treatment options compared

TreatmentHow it is usedUsually suited to
Topical creams and ointmentsApplied to the patchesSmaller or localised patches
Phototherapy (light treatment)Regular sessions under controlled UV light at a clinicWider areas of skin
Laser treatmentTargeted light on specific patchesStable, limited patches
Oral upadacitinib (RINVOQ)One tablet a day, on prescriptionNon-segmental vitiligo needing systemic therapy, age 12+

Looking for a dermatologist?

Find dermatologists and skin clinics in the UAE on MediFinder

Frequently Asked Questions

It is RINVOQ (upadacitinib), a once-daily tablet. The Emirates Drug Establishment approved it in August 2026 for non-segmental vitiligo in people aged 12 and over who need systemic treatment.

The Emirates Drug Establishment and the Emirates Dermatology Society say the UAE is the first country to approve this use. The maker, AbbVie, also announced a European Commission approval on 29 July 2026.

No. It is approved only for non-segmental vitiligo that needs systemic therapy, and only on prescription. A dermatologist will check your type of vitiligo, your health history and your blood tests before deciding.

Repigmentation is slow with every treatment. In the main studies of the oral pill, results were measured after 48 weeks, so ask your dermatologist what to expect for your skin.

Start with a dermatologist. They can confirm the diagnosis and explain creams, light therapy, laser or the oral pill. You can compare dermatologists and skin clinics across the UAE on MediFinder.

Sources: Khaleej Times, Gulf News, WAM, ILDS, AbbVie, UAE Barq. Photo: Simone Trovato Monastra, CC BY-SA 4.0, via Wikimedia Commons. This article is for information only and is not medical advice.

Ready to see a specialist?

Find a dermatologist on MediFinder

Comments

Be the first to comment!

Find care on Medifinder